Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

of less than 70 mg/dL. For Moderately High-Risk patients, the target is less than 130 mg/dL. Over 20 million people in the U.S. in the High-Risk and Moderately High-Risk categories are failing to meet recommended LDL-C targets using currently available lipid-lowering therapies.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS 301012 in treating high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a b
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
(Date:8/29/2014)... 29, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... and consumables to the medical, research and veterinary markets, ... Chief Executive Officer, will present at the CL King ... Tuesday, September 9, 2014 at 12:30 p.m. ET. The ... Hotel in New York City . ...
(Date:8/29/2014)... VANCOUVER, British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" ... 2014 fiscal year-end financial statements.  The Company recently changed ... to facilitate an application to list its common stock ... possible. DelMar,s financial statements as filed with ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... ALEXANDRIA, Va., April 14, 2011 Oxford Finance Corporation ... it closed a $2 million equipment loan with Synta ... to manufacture compounds for use in Synta,s ongoing clinical ... diseases. "Synta Pharmaceuticals has a diverse drug ...
... April 14, 2011 Beacon Enterprise Solutions Group, ... emerging global leader in the design, implementation and ... today announces the signing of a third US-based ...   http://photos.prnewswire.com/prnh/20101021/DA85933LOGO ) Beacon has ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2Beacon Announces Agreement With New Fortune 500 Pharmaceutical Client 2Beacon Announces Agreement With New Fortune 500 Pharmaceutical Client 3
(Date:9/1/2014)... September 01, 2014 Registration is now open ... 5K and 1-Mile Race to be held on Sunday, September ... Court Yard at Harmon Meadow in Secaucus, New Jersey. All ... a national nonprofit dedicated to restoring a sense of self, ... members and our military families. , General registration is $30 ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
(Date:9/1/2014)... Pastor Thompson is an ordained minister and previously ... is a licensed minister through the Church of the Nazarene ... in New Mexico, Colorado and North Dakota. He and his ... He also has two beautiful daughters, Brianna, 22 and ... from Nazarene Bible College, in Colorado Springs and is currently ...
(Date:9/1/2014)... September 01, 2014 Psychogenic Non-epileptic Seizures ... a psychological disorder that can have devastating effects on ... like epileptic seizures however, they are not produced by ... triggers. It is estimated that the numbers of ... by multiple sclerosis. , Dr. Lorna Myers, ...
(Date:8/31/2014)... August 31, 2014 MYMOBILEUNI (MMU) ... utilizing social media marketing tools access to digital, ... MMU will utilize all tools to reach and ... for our multiple learning channels. , MMU, today ... and an authoring tool that applies social networking ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 3
... ... What can we do about that? Awareness is the first step toward responsible and ... (PRWEB) March ... but also for the health of the consumer. Conventional clothing has chemical residues which ...
... Three ... and pulmonary embolism (PE), a growing public health problem estimated to affect nearly 1 ... ... national workshop have been released to address deep-vein thrombosis (DVT) and pulmonary embolism (PE), ...
... possible long-term effects, experts say, , WEDNESDAY, March 10 ... be an alternative to the widely used statin medications ... and American researchers report. , In the trial, various ... thyroid hormone, were added to statin treatment for 168 ...
... , ... ... ... Funds from Operations Modified (FFOM), excluding the non-recurring events summarized below, for fourth quarter 2009 was $7.9 million , or $0.16 per share and operating partnership unit. , ...
... ultrasound guidance, treating tumors with extreme heat or moderate ... early research presented at the second AACR Dead Sea ... Laboratory to the Clinic, held March 7-10, 2010. ... are beneficial in curing both malignant and benign tumors ...
... BLACKBURN, United Kingdom , March 10 Will the Rt Hon Andy Burnham MP Ban all Tobacco products on 21st June 2010 ? , ... , , ... ... The MHRA, the nation,s Health regulators, have created for Mr. ...
Cached Medicine News:Health News:Organic Clothing can be as Crucial to Your Health as Organic Food or Yoga 2Health News:Organic Clothing can be as Crucial to Your Health as Organic Food or Yoga 3Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 2Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 3Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 4Health News:Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism 5Health News:Alternative to Statins Shows Promise 2Health News:Alternative to Statins Shows Promise 3Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 2Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 3Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 4Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 5Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 6Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 7Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 8Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 9Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 10Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 11Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 12Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 13Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 14Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 15Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 16Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 17Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 18Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 19Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 20Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 21Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 22Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 23Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 24Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 25Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 26Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 27Health News:Cogdell Spencer Inc. Reports Fourth Quarter and Year End 2009 Financial Results 28
Disposable Cannula Cuffless Tracheostomy Tubes...
Disposable Cannula Cuffed Tracheostomy Tubes...
... CARE Double Swivel Elbow is designed ... provide flexibility without connectors. Features one ... for better feel. Numbered catheter allows ... catheter advance. Offers multiple tracheostomy sizes, ...
... soft, flexible whistle tip suction catheter ... that includes: One pair of vinyl ... ml bottle of sterile saline. Components ... with cuffed gloves and catheter inside ...
Medicine Products: